UnitedHealth Group's stock has surged over 30% in the past month following a strong first-quarter earnings report, which included an improved medical care ratio and raised full-year earnings guidance. However, concerns remain regarding membership attrition and weaker performance in its healthcare services segment, leading analysts to suggest that the stock may now be overpriced for new investors.
UnitedHealth's recent 30% stock surge, driven by improved medical care ratio and raised earnings guidance, may have already priced in the company's underlying improvements. At about 19 times the 2026 earnings outlook, the stock is not excessively expensive but might not offer enough value given the uncertainties like membership attrition and Optum's weaker earnings. It might be prudent to hold off on new investments in UnitedHealth until more favorable conditions or prices emerge.